Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

Mes dernières consult.
Most popular
Financials ($)
Sales 2017 79,3 M
EBIT 2017 7,39 M
Net income 2017 -2,93 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 119 M
EBIT 2018 18,5 M
Net income 2018 7,12 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 60,18
EV / Sales2017 5,53x
EV / Sales2018 3,67x
Capitalization 366 M
More Financials
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
10/26Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
09/20 TELIGENT : Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0.1%
09/19 Teligent, Inc. Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0..
09/18 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Departure of Directors or Certain Of..
09/18 TELIGENT, INC. : Change in Directors or Principal Officers, Other Events, Financ..
09/18 Teligent, Inc. Appoints Thomas J. Sabatino, Jr. to Board of Directors
09/12 Teligent, Inc. to Present at Morgan Stanley 15th Annual Global Healthcare Con..
08/23 TELIGENT : Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%, Emo..
08/22 TELIGENT : Receives Fourth FDA Approval on 2017
08/22 Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.0..
08/08 TELIGENT : reports 2Q loss
More news
Sector news : Pharmaceuticals - NEC
09/24 SAP to buy customer management software firm Gigya
09/22DJCorrection to Sept. 7 Harvey Rebuilding Article
09/22 Korea tensions keep European shares in check before Germany vote
09/22 Bettencourt death stirs speculation about L'Oreal ownership
09/22 China online insurer ZhongAn prices Hong Kong IPO at top end, raises $1.5 bil..
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,40 $
Spread / Average Target 37%
EPS Revisions
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633